Rani Therapeutics Holdings, Inc. business relationships
Companies named in Rani Therapeutics Holdings, Inc.’s 10-K filed 2026-03-26, and public companies whose annual reports name Rani Therapeutics Holdings, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 71 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Layers: GLP-1 & obesity
Named in Rani Therapeutics Holdings, Inc.’s annual report 4
“Early-stage device-based technologies such as the SOMA and LUMI from the Novo Nordisk-MIT collaboration were reported to be in early clinical and preclinical stages, respectively.” SEC filing
“Adalimumab, sold by AbbVie Inc. under the brand name Humira, generated U.S. sales of approximately $7.14 billion in 2024.” SEC filing
“*** Ustekinumab and adalimumab biosimilars are supplied by Celltrion, Inc. Celltrion grants Rani a license and drug supply for each drug.” SEC filing
“In June 2021, we entered into an Amended and Restated Exclusive License Agreement with InCube Labs, LLC ("ICL"), which replaced the 2012 Exclusive License Agreement between ICL and Rani LLC, as amended in 2013, and terminated the 2012 Intellectual Property Agreement between ICL and Rani LLC, as amen...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.